Redefining Standard-of-Care: In Rare Cancers, the Experiences of Two Patients May Be Enough
October 24th 2012As more individual cancers undergo molecular profiling, we can anticipate that the scenario in which a targeted drug demonstrates rather remarkable clinical activity against a rare tumor type will become increasingly common.
Read More
Targeting Non-Mutant EGFR: Genetic and Clinical Biomarkers May Help Validate Use of Inhibitors
June 25th 2012A recent study suggests patients may be selected for therapy based on the number of EGFR gene copies, and evaluated for clinical benefit based on the severity of the rash that often develops.
Read More
The Retreatment Strategy: Would It Work With the Same Molecularly Targeted Therapy?
February 23rd 2012Patients who initially exhibit a response to a particular strategy may achieve substantial clinical benefit if the same or very similar agents are delivered after variably defined treatment-free intervals.
Read More
2 Landmark Trials Suggest Changes in Practice; Brachytherapy Controversy Attracts Attention
February 20th 2012This commentary will highlight 2 phase III randomized trials and a retrospective review of a large national database that has been strongly criticized based on its overall conclusions.
Read More
Pharmacogenomics in Action: CYP2D6 Breast Cancer Debate Shows Intricacies of Genotyping
December 21st 2011Recently reported and truly impressive clinical trial data have revealed the relevance of administering antineoplastic agents specifically and prospectively targeted to molecular abnormalities.
Read More